https://www.bioworld.com/rss en-us A flurry of deals focused on the neurological disease space in 2026 suggest large biopharma companies are searching for the next best therapeutics for everything from epilepsy and narcolepsy to post-traumatic stress disorder and hyperphagia. http://www.bioworld.com/articles/730616 Fri, 24 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730616-neuro-deals-aplenty-ucbs-1b-takeover-of-neurona-the-latest Epileptic brain and abnormal EEG wave discharges Chengdu Kanghong Pharmaceutical Group Co. Ltd. is developing a nonopioid Nav1.8 inhibitor, KHN-702. The effects of KHN-702 were evaluated both in vitro and in vivo, in a plantar incision pain model, and results were presented at the recent American Academy of Neurology meeting in Chicago. http://www.bioworld.com/articles/730637 Fri, 24 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730637-khn-702-as-a-potent-nonopioid-analgesic Pain illustration At the recently concluded meeting of the American Academy of Neurology, Synendos Therapeutics AG reported preclinical data from the pharmacological characterization of SYT-510, which is the first selective endocannabinoid reuptake inhibitor (SERI) to enter the clinic for the potential treatment of disorders affecting the CNS, such as anxiety or movement disorders. A new class of endocannabinoid system (ECS) modulators, SERIs potently and selectively inhibit endocannabinoid reuptake to help the ECS restore normal brain function under disease conditions. http://www.bioworld.com/articles/730585 Thu, 23 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730585-synendos-first-in-class-seri-effective-in-models-of-anxiety Silhouette of head and brainwith fractal art Optimism rose for what could be the first CAR T therapy in autoimmune disease as Kyverna Therapeutics Inc. made public a positive primary analysis from its registrational trial, KYSA-8, of mivocabtagene autoleucel (miv-cel, KYV-101) in stiff-person syndrome. Kyverna plans to submit a BLA to the U.S. FDA in the first half of this year. http://www.bioworld.com/articles/730495 Wed, 22 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730495-walking-the-talk-kyverna-phase-ii-stiffens-miv-cel-car-t-case Woman stretching her arms and hands Researchers from Xenon Pharmaceuticals Inc. described the preclinical efficacy of XPC-837 in models of Dravet syndrome, a severe developmental and epileptic encephalopathy most commonly caused by de novo loss of function mutations in the SCN1A gene. SCN1A gene.]]> http://www.bioworld.com/articles/730539 Tue, 21 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730539-xpc-837-restores-network-dysfunction-in-dravet-syndrome-models Brain and DNA Vanda Pharmaceuticals Inc. presented data this week at the annual American Academy of Neurology conference regarding allele-specific antisense oligonucleotides (ASOs) that specifically target the mutant p.A53T allele from the SNCA gene while preserving the expression of the wild-type allele. The mutant allele is associated with increased risk of early-onset Parkinson’s disease (PD) and current ASOs target SNCA regardless of its mutation status. SNCA gene while preserving the expression of the wild-type allele. The mutant allele is associated with increased risk of early-onset Parkinson’s disease (PD) and current ASOs target SNCA regardless of its mutation status.]]> http://www.bioworld.com/articles/730537 Tue, 21 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730537-aso-targeting-snca-pa53t-shows-promise-in-parkinsons Steadying hand while reaching for glass Watchers of the percolating myasthenia gravis space are waiting eagerly for data from Dianthus Therapeutics Inc.’s phase II Magic study testing DNTH-103, an active C1s inhibitor, compared to placebo in patients with anti-AChR-positive generalized disease. http://www.bioworld.com/articles/719349 Mon, 21 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/719349-complement-ary-approaches-fcrn-holds-ground-in-myasthenia-gravis Illustration of motor neuron connecting to muscle fiber Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the rare autoimmune neuromuscular disorder at the 2025 American Academy of Neurology conference. http://www.bioworld.com/articles/719310 Tue, 15 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/719310-remegens-lupus-drug-surfaces-with-phase-iii-myasthenia-gravis-data Telitacicept packaging Credit: Remegen Co. Ltd. As developers continue to search for better amyotrophic lateral sclerosis (ALS) therapies, Neurosense Therapeutics Ltd. turned up some hopeful findings from its phase IIb Paradigm trial with PrimeC. The drug, a combination therapy (ciprofloxacin and celecoxib) designed to target multiple ALS pathways, is having salutary effects on microRNA modulation (miRNA), Neurosense said, with the study showing a “profound and consistent” downregulation of 161 mature miRNAs across all time points in the double-blind period of the experiment. http://www.bioworld.com/articles/718993 Wed, 09 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/718993-neurosense-phase-ii-combo-to-hail-new-paradigm-in-als Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the rare autoimmune neuromuscular disorder at the 2025 American Academy of Neurology conference. http://www.bioworld.com/articles/718992 Wed, 09 Apr 2025 11:00:00 -0400 https://www.bioworld.com/articles/718992-remegens-lupus-drug-surfaces-with-phase-iii-myasthenia-gravis-data Telitacicept packaging Credit: Remegen Co. Ltd. Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd. has developed a new small-molecule oral compound for the treatment of Parkinson’s disease, FHND-1002, which demonstrated neuronal protection in models of neurodegenerative diseases and neuron trauma. http://www.bioworld.com/articles/707958 Fri, 26 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707958-fhnd-1002-regenerates-neuron-damage-in-parkinsons-disease-model Proof-of-concept findings had shown that mRNA silencing of striatal Cav1.3 channels prevented and reversed established levodopa-induced dyskinesia in parkinsonian rats, with these effects being maintained in aged rats. http://www.bioworld.com/articles/707804 Tue, 23 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707804-aav-cav13-shrna-ameliorates-parkinsonian-symptoms-in-aged-macaques Steadying hand while reaching for glass The generation of pathogenic autoantibodies is a crucial event in the development of inflammation and complement activation, leading to immune cell responses. http://www.bioworld.com/articles/707778 Mon, 22 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707778-pan-igg-protease-s-1117-reduces-igg-levels-and-ameliorates-nephritis-in-murine-model Kidneys Vanishing white matter disease (VWM) is a rare and progressive leukoencephalopathy caused by loss-of-function mutations, in a recessive pattern of inheritance, in any of the genes encoding eIF2B, a guanine nucleotide exchange factor for eIF2 and an effector of the integrated stress response (ISR). At last week’s American Academy of Neurology meeting, Calico Life Sciences LLC and Abbvie Inc. presented preclinical results for their brain-penetrant compound ABBV-CLS-7262 (fosigotifator sodium tromethamine) in VWM. http://www.bioworld.com/articles/707776 Mon, 22 Apr 2024 09:00:00 -0400 https://www.bioworld.com/articles/707776-eif2b-activator-abbv-cls-7262-shows-promise-in-vanishing-white-matter-disease The U.S. FDA’s green light April 17 for Abbvie Inc. to expand the label of Qulipta (atogepant) – the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist for migraine, with language that includes prevention of such headaches chronically in adults – provided a welcome addition to the arsenal, but sufferers are still waiting for an improved remedy. Vaxxinity Inc. just might have it. And with a vaccine, no less. http://www.bioworld.com/articles/696325 Fri, 21 Apr 2023 12:00:00 -0400 https://www.bioworld.com/articles/696325-head-of-the-class-vaxxinity-could-ease-migraine-ache-with-new-cgrp-approach New and updated preclinical and clinical data presented by biopharma firms at the European Academy of Neurology Congress, including: Bristol Myers Squibb, Horizon, Teva. http://www.bioworld.com/articles/520124 Tue, 28 Jun 2022 11:00:00 -0400 https://www.bioworld.com/articles/520124-conference-data-for-june-28-2022-ean New and updated preclinical and clinical data presented by biopharma firms at the American Academy of Neurology annual meeting, including: Clene, Emalex, Genentech, H. Lundbeck, Horizon, Mitsubishi, Neurelis, Neurocrine, Neuroderm, TG. http://www.bioworld.com/articles/517574 Mon, 04 Apr 2022 11:00:00 -0400 https://www.bioworld.com/articles/517574-conference-data-for-april-4-2022-aan New and updated preclinical and clinical data presented by biopharma firms at the American Academy of Neurology Annual Meeting, including: Autobahn, Avadel, Lundbeck, Prothena, Teva. http://www.bioworld.com/articles/506082 Mon, 19 Apr 2021 11:00:00 -0400 https://www.bioworld.com/articles/506082-conference-data-for-april-19-2021-aan